乌鸦传媒

<乌鸦传媒 class="page-title">Meeting Coverage

HIV Glasgow

<乌鸦传媒 class="page-description">The International Congress on Drug Therapy in HIV Infection
DTG-Based Regimen Comparable, But Not Superior, to EFV-400

Dolutegravir efficacy non-inferior to efavirenz-based regimen at week 48

image
<乌鸦传媒 class="section_title">Latest HIV Glasgow Meeting Coverage
Novel Agent for Refractory HIV Patients Hits the Mark

Fostemsavir maintained virologic response through week 48 in ongoing phase III trial

November 1, 2018
Longer-Term Phase III Data Promising for Single-Tablet Symtuza

Week 96 results continue to show non-inferiority in treatment-naive HIV+ adults

October 31, 2018
Experts: Don't Overlook Mental Health in People Living With HIV

Literature shows prevalence of mental health, depression in this population

October 31, 2018
Combination Approach May Be Key to Achieving HIV 'Cure'

Look to oncology space for benchmarks, immunotherapy research, experts say

October 30, 2018
Confirmed: PrEP Is Safe for High-Risk Patients

No significant difference in grade 3/4 adverse events, meta-analysis finds

October 30, 2018
Mixed Results on CV Biomarkers With Switch to DTG-Based Tx

Substudy finds competing markers of decreased, increased risk of CV events

October 29, 2018
<乌鸦传媒 class="section_title"> Latest HIV/AIDS Meeting Coverage